XTalks

JANUARY 5, 2021

There will also be more focus on digitization of research and development and manufacturing spaces to increase efficiencies and interconnectivity in the pharma, biotech and medical device industries. The test identifies SARS-CoV-2 protein fragments from nasal swab samples. 1. COVID-19 Pandemic: An Evolving Era.

Life Science 98

Life Science Clinical Trials Clinical Trials Trials 98

XTalks

DECEMBER 17, 2021

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. Life Science Innovations: Malaria and Influenza Vaccines.

Life Science 98

Life Science Vaccination Vaccine Trials 98

XTalks

NOVEMBER 26, 2024

This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction. BridgeBio’s leadership, including Neil Kumar, emphasizes the significance of Attruby’s approval as a cornerstone in their mission to develop therapies for genetic diseases.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

Pharmaceutical Technology

MARCH 10, 2023

On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. Personalised medicines will also be developed at the centre.

Gene Therapy 264

Gene Therapy Manufacturing Gene Clinical Trials 264

XTalks

MARCH 31, 2023

By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability. The proteins will be analyzed back on Earth using techniques such as X-ray diffraction and compared with crystals from the same biologics grown on Earth.

Protein 97

Protein Research Development Manufacturing 97

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 94

Protein Development Clinical Trials Clinical Trials 94

pharmaphorum

JULY 18, 2022

“It is programmed and coded for the production of the full-length spike protein of the coronavirus. It then elicits an immune response against that spike protein. Pierre has over 35 years of experience in the global life science industry in specialty care, vaccines and immunotherapy and has been CEO of several start-ups.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

pharmaphorum

JULY 26, 2021

The most complete database of protein structures ever assembled, developed with the help of Google’s artificial intelligence unit DeepMind, has been made freely available to researchers around the world. Around a third of the structures are considered to be detailed and precise enough to allow drug design.

Protein 130

Protein Genome Genomics Life Science 130

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 Glenn, president of research and development at Novavax, in a news release. “It

Protein 97

Protein Vaccination Vaccine Trials 97

Scienmag

FEBRUARY 5, 2021

Membrane-localized phage proteins may also help revitalize, enhance existing antibiotics A study from the Center for Phage Technology, part of Texas A&M’s College of Agriculture and Life Sciences and Texas A&M AgriLife Research, shows how the “hidden” genes in bacteriophages — types of viruses that infect and destroy (..)

Gene 74

Gene Bacteria Life Science Development 74

XTalks

JANUARY 21, 2025

The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca. Datroway leverages DXd technology to precisely target cancer cells.

Antibody 105

Antibody FDA Approval HR Trials 105

Pharmaceutical Technology

JUNE 4, 2023

There are two main genes in the AAV genome, rep and cap, which encode nine different proteins. Transcription of the rep gene is initiated from the p5 or p19 promoters to, respectively, produce the large (Rep78 and Rep68) and small (Rep52 and Rep40) nonstructural Rep proteins.

Gene 262

Gene Gene Therapy Genetics DNA 262

XTalks

JANUARY 7, 2025

Symvess is a one-time, single-use, acellular tissue-engineered vessel (ATEV) composed of human extracellular matrix proteins. While Symvess focuses on arterial repair, other developments like AQUACEL Ag+ Extra, Molnlycke Health Cares wound management technologies and Traumagel are advancing care in related areas.

FDA Approval 105

FDA Approval Engineer Clinical Trials Clinical Trials 105

XTalks

OCTOBER 16, 2024

In this episode, Vera spoke with Dr. Sam Lee, Co-Chief Executive Officer and President of Cocrystal Pharma, a clinical-stage biotech company focusing on antiviral drug development with a unique structure-based drug discovery platform. As the conversation wraps up, Dr. Lee discusses his excitement for the future of antiviral drug development.

Development 64

Development Drugs Life Science Protein 64

XTalks

MAY 29, 2024

In this episode, Ayesha spoke with Sam Lee, PhD, Co-Chief Executive Officer and President of Cocrystal Pharma , a company developing novel antiviral therapeutics against COVID-19 and other coronaviruses, influenza viruses and noroviruses. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science FDA Approval Drugs Development 52

Pharmaceutical Technology

FEBRUARY 13, 2023

Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. To tackle this, companies have developed different ways to focus on the gene.

Research 264

Research Gene Gene Therapy Genome 264

XTalks

JANUARY 19, 2022

The research shows that exercise increases levels of synaptic proteins in the brain involved in maintaining and strengthening neuronal connections. The researchers also found these proteins could be protective even in people with dementia and other neurodegenerative diseases like Alzheimer’s.

Life Science 52

Life Science Protein Development Research 52

XTalks

NOVEMBER 21, 2024

It is characterized by the build-up of abnormal protein deposits in the heart tissue, leading to stiffening of the heart walls and impairing its ability to pump blood effectively. The FDA’s Total Product Lifecycle Advisory Program supported the streamlined development and clearance of the EchoGo Amyloidosis device.

Production 105

Production Protein Life Science Trials 105

XTalks

NOVEMBER 8, 2024

Top Hospital-Based Healthcare Innovations Google DeepMind AlphaFold 3: Rendering Molecules in HD Drug discovery often hinges on predicting how proteins interact with each other. Understanding these interactions is like solving a three-dimensional puzzle with thousands of pieces. hours earlier than traditional methods.

Doctors 104

Doctors Doctor Protein Nurses 104

XTalks

NOVEMBER 6, 2024

Gelteq’s formulations enable the delivery of various active ingredients like branched-chain amino acids, protein, caffeine and essential minerals, opening applications in sports performance, nutrition and therapeutic use.

Drug Delivery 104

Drug Delivery Drugs Bioequivalency Bioavailability 104

Pharmaceutical Technology

APRIL 18, 2023

Innovation S-curve for the pharmaceutical industry HIV peptides is a key innovation area in pharmaceuticals HIV peptides are fragments derived from HIV envelope gp160 protein, the HIV matrix/capsid proteins, and the HIV gag, pol and env gene products.

Protein 147

Protein Vaccination Vaccine Production 147

Pharmaceutical Technology

MAY 8, 2023

This protein also serves as a target for neutralizing antibodies, which can be used to develop for therapeutic as well as diagnostic applications. There are four types of influenza viruses: A, B, C, and D. Hemagglutinin (HA), an envelope glycoprotein on the influenza virion enables the virus to enter and spread between cells.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

XTalks

AUGUST 5, 2020

Single cell RNA sequencing technology has been extensively applied to understand heterogeneity among tumor cells, within the tumor microenvironment and during cell development. Tracing the development pathway of neuronal progenitors using single cell RNA seq. Leading Innovations in Single Cell Technology.

Gene Expression 112

Gene Expression Development RNA Drugs 112

XTalks

MAY 10, 2023

The treatment, an antisense oligonucleotide developed by Biogen, targets abnormal proteins arising from SOD1 mutations, which are associated with the development of ALS in some patients. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 40

Life Science Vaccination Vaccine FDA Approval 40

XTalks

OCTOBER 12, 2021

Last week, a study that “stumbled upon” a vaccine for rheumatoid arthritis (RA) was published in the Proceedings of the National Academy of Sciences. The experimental arthritis vaccine was developed by researchers at the University of Toledo (UToledo) and is a major breakthrough for rheumatoid arthritis and other autoimmune diseases as well.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

XTalks

MAY 10, 2022

On Saturday, researchers at the Children’s Hospital of Philadelphia (CHOP) have announced that they developed and launched a new bioinformatics software tool called CancerVar (cancer variant interpretation). Why Was CancerVar Developed? What is CancerVar? This software is implemented in Python and has a user-friendly web server.

Bioinformatics 98

Bioinformatics Development Gene Genome 98

pharmaphorum

MARCH 23, 2021

US biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like drug conjugate (VDC) for a cancer that affects the eye into late-stage development. The post Aura raises $80m to develop its virus-like cancer drugs appeared first on.

Development 70

Development Drugs Immune Response Life Science 70

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Merck KG, is a science and technology company.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

XTalks

AUGUST 8, 2024

Dieterich has a PhD in synthetic organic chemistry, an MBA from Imperial College London and a wealth of experience in drug development and chemistry, manufacturing and control (CMC) activities. Abzena is a leader in bioconjugation and ADC development. They act by modifying protein expression, offering new treatments for rare diseases.

Development 64

Development Medicine Antibody Protein 64

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. The UK Government is behind this effort.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

pharmaphorum

MARCH 9, 2021

Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. ExeVir is not the first company to spin out of VIB to focus on camelid antibodies.

Antibody 98

Antibody Life Science Scientist Development 98

XTalks

NOVEMBER 23, 2021

Canadian pharma and biotech contract development and manufacturing organization (CDMO) Biovectra has announced plans for building one of the first state-of-the-art mRNA vaccine and biomanufacturing facilities in Canada. If all goes well, it could become Canada’s first domestically developed COVID-19 vaccine. million, respectively. “We

Manufacturing 98

Manufacturing Vaccination Vaccine Drugs 98

XTalks

JULY 28, 2020

Using a database developed by Brian Shoichet, PhD, a professor in the Department of Pharmaceutical Chemistry at UCSF, Shoichet and his team worked with Laszlo Urban, PhD, global head of preclinical safety profiling at NIBR, to identify possible interactions between commonly-used excipients and human enzymes and receptors.

Protein 103

Protein Drugs In-Vitro Scientist 103

XTalks

AUGUST 8, 2022

Medicxi is a prominent international life sciences investment firm that invested in over 60 portfolio companies such as Versanis Bio, Rivus Pharmaceuticals, Capella Bioscience and more. One of Medicxi’s portfolio companies called MiroBio is set to be acquired by Gilead Sciences for approximately $405 million in cash.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

Delveinsight

JULY 29, 2021

TNB-585 complements Amgen’s existing prostate cancer portfolio, including acapatamab (formerly AMG 160), a half-life extended, PSMA-targeted BiTE; and AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, which is both in phase 1. executive vice president of research and development at Amgen. Reese, M.D.,

Drugs 98

Drugs Protein Life Science Development 98

XTalks

APRIL 13, 2021

While it has been known for about five decades now that patients with Parkinson’s disease have a higher likelihood of developing melanoma than the general population, the exact reasons for this were unknown. The scientists found that the amyloid-forming protein is expressed at higher levels in melanoma cells than in normal healthy skin.

Research 98

Research Protein In-Vitro Scientist 98